MedTrace Logo

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

NCT01719549 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2020-01-07

No results posted yet for this study

Summary

This is a single-center, prospective, single-arm, open-label phase II study

Conditions

Interventions

DRUG

Dovitinib

* Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule * Study drug: TKI258 capsule * Dose: 500mg p.o. qd * Every 3 weeks

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Yoon-Koo Kang, PhD · Asan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2016-02-29
Completion
2016-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719549 on ClinicalTrials.gov